Cart
sales@molnova.com
PIK-108
CAS No. 901398-68-3
PIK-108( PIK 108 | PIK108 )
Catalog No. M24934 CAS No. 901398-68-3
PIK-108 is an allosteric inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunits β and δ (PI3Kβ/δ).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 102 | In Stock |
|
| 2MG | 49 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 150 | In Stock |
|
| 25MG | 255 | In Stock |
|
| 50MG | 360 | In Stock |
|
| 100MG | 498 | In Stock |
|
| 200MG | 684 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePIK-108
-
NoteResearch use only, not for human use.
-
Brief DescriptionPIK-108 is an allosteric inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunits β and δ (PI3Kβ/δ).
-
DescriptionPIK-108 is an allosteric inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunits β and δ (PI3Kβ/δ).
-
In VitroPIK-108 (0.1-10 μM; 1 hour) blocks phosphorylation of PKB/Akt.Western Blot Analysis Cell Line:Glioma cell lines expressing wild-type PTEN Concentration:0.1, 0.5, 1, 4, and 10 μM Incubation Time:1 hour Result:Showed variable inhibition of PKB/Akt phosphorylation but exhibited a trend toward reducing PKB/Akt phosphorylation more effectively in mutant PTEN-expressing cell lines than in wild-type PTEN-expressing cell lines.
-
In Vivo——
-
SynonymsPIK 108 | PIK108
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3Kα|PI3Kβ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number901398-68-3
-
Formula Weight364.44
-
Molecular FormulaC22H24N2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:45 mg/mL?(123.48 mM;?Need ultrasonic)
-
SMILESO=C1C=C(N2CCOCC2)OC3=C(C(NC4=CC=CC=C4)C)C=C(C)C=C13
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Certal V, Halley F, Virone-Oddos A, Delorme C, Karlsson A, Rak A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Carry JC et al.. (2012) Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. J. Med. Chem., 55 (10): 4788-805. [PMID:22524426]
molnova catalog
related products
-
GDC-0941 dimethanesu...
A potent, selective, orally bioavailable inhibitor of class I PI3Ks with IC50 of 3/33/3/75 nM for p110α/β/γ/δ, respectively.
-
Zandelisib
Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.
-
PI3K-IN-38
PI3K-IN-38 is an orally available and potent PI3K inhibitor with an IC50 value of 0.541 μM for PI3K-α. PI3K-IN-38 exhibits anticancer and anti-inflammatory activity and inhibits tumor growth in vivo.
